News

April 18, 2016April 18, 2016

Engineered Bacteria Seen in Phase 1 Trial in Malignant Pleural Mesothelioma Patients to Improve Response and Cancer Control

News

A new study, presented on April 14 at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland, holds promise for the treatment of pleural mesothelioma. Results from a Phase 1b trial showed ... Read more

April 15, 2016April 15, 2016

Young Mesothelioma Researcher Among Winners of AXA Achievement Scholarship

News

AXA, a financial services company, recently announced the 52 student winners of the 2016 AXA Achievement Scholarship, one from each of the 50 states in the United States plus Puerto Rico and Washington, ... Read more

April 14, 2016April 14, 2016

U.K. Company Offering Schools Free Training in Asbestos Management Throughout April

News

Each year, the Asbestos Disease Awareness Organisation (ADAO) dedicates April 1-7 to increasing awareness about asbestos and preventing exposure, bringing experts and people with mesothelioma and other asbestos-related diseases together worldwide to ... Read more

April 13, 2016April 13, 2016

Radiotherapy May Trigger Mesothelioma, But Study Considers Risk to Be Minuscule

News

Radiotherapy used to treat solid cancers increases the risk of developing mesothelioma as a secondary cancer, according to a study published in the journal Cancer Medicine. The risk, however, is ... Read more

April 12, 2016April 12, 2016

Global Asbestos Week Closes with U.S. Surgeon General Statement on Widespread Use and Risks of Asbestos

News

The nonprofit Asbestos Disease Awareness Organization (ADAO) welcomed the recent statement by Dr. Vivek H. Murthy, the U.S. Surgeon General, concerning the dangers of asbestos. His statement was given at the close ... Read more

April 11, 2016April 11, 2016

Mesothelioma Study Suggests a Cancer-Promoting Pathway Could Be Redirected to Fight Disease

News

Malignant pleural mesothelioma patients who have high levels of the signaling factor AKT1 have a worse prognosis, researchers reported in the journal Oncotarget. Blocking the signaling pathway, however, boosts the ... Read more

April 8, 2016April 8, 2016

COMP Favors Orphan Drug Designation for SELLAS’ WT1 Vaccine to Treat MPM

News

The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has given a positive opinion in support of orphan drug designation for the WT1 cancer vaccine (galinpepimut-S), which SELLAS Life ... Read more

April 7, 2016April 7, 2016

SELLAS to Present Mesothelioma Phase 2 Trial Results of Cancer Vaccine at Upcoming Meetings

News

SELLAS Life Sciences Group announced that it will present the results of a Phase 2 clinical trial evaluating the WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) at the 13th ... Read more

April 6, 2016April 6, 2016

SELLAS’ WT1 Vaccine for Mesothelioma and Other Cancers Renamed Galinpepimut-S by US Council

News

SELLAS Life Sciences Group announced that its WT1 vaccine, a clinical-stage immunotherapy for a wide range of hematologic cancers and solid tumors, including malignant pleural mesothelioma, has been approved to be named galinpepimut-S by ... Read more

April 5, 2016April 5, 2016

Pleural Mesothelioma and Its Possible Link to Inflammatory Macrophage MIF Continues to Baffle

News

The inflammatory macrophage migration inhibitory factor (MIF) might affect the development of malignant pleural mesothelioma. A study into the factor’s effect on cells derived from different mesothelioma cell types and stages, however, ... Read more